MY201105A - Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus - Google Patents

Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Info

Publication number
MY201105A
MY201105A MYPI2019004285A MYPI2019004285A MY201105A MY 201105 A MY201105 A MY 201105A MY PI2019004285 A MYPI2019004285 A MY PI2019004285A MY PI2019004285 A MYPI2019004285 A MY PI2019004285A MY 201105 A MY201105 A MY 201105A
Authority
MY
Malaysia
Prior art keywords
hemi
hepatitis
sulfate salt
nucleotide
virus
Prior art date
Application number
MYPI2019004285A
Other languages
English (en)
Inventor
Moussa Adel
Sommadossi Jean-Pierre
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62977563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY201105(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of MY201105A publication Critical patent/MY201105A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Storage Device Security (AREA)
MYPI2019004285A 2017-02-01 2018-01-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus MY201105A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762453437P 2017-02-01 2017-02-01
US201762469912P 2017-03-10 2017-03-10
US201762488366P 2017-04-21 2017-04-21
US201762575248P 2017-10-20 2017-10-20
PCT/US2018/016301 WO2018144640A1 (en) 2017-02-01 2018-01-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Publications (1)

Publication Number Publication Date
MY201105A true MY201105A (en) 2024-02-06

Family

ID=62977563

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019004285A MY201105A (en) 2017-02-01 2018-01-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Country Status (30)

Country Link
US (6) US10519186B2 (https=)
EP (2) EP3577124B1 (https=)
JP (3) JP7066728B2 (https=)
KR (3) KR102335193B1 (https=)
CN (2) CN110248951B (https=)
AU (3) AU2018215203B2 (https=)
CA (2) CA3048033C (https=)
CO (1) CO2019009215A2 (https=)
DK (1) DK3577124T3 (https=)
ES (1) ES3009733T3 (https=)
FI (1) FI3577124T3 (https=)
GE (2) GEP20227457B (https=)
HR (1) HRP20250266T1 (https=)
HU (1) HUE070331T2 (https=)
IL (3) IL288737B (https=)
LT (1) LT3577124T (https=)
MX (2) MX394394B (https=)
MY (1) MY201105A (https=)
NZ (1) NZ780244A (https=)
PH (1) PH12019550113A1 (https=)
PL (1) PL3577124T3 (https=)
PT (1) PT3577124T (https=)
RS (1) RS66554B1 (https=)
SG (2) SG11201906163TA (https=)
SI (1) SI3577124T1 (https=)
SM (1) SMT202500048T1 (https=)
TW (2) TWI866273B (https=)
UA (1) UA127407C2 (https=)
WO (1) WO2018144640A1 (https=)
ZA (3) ZA201904336B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US20250109163A1 (en) * 2017-02-01 2025-04-03 Atea Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EP3773753A4 (en) * 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP2022510014A (ja) * 2018-12-05 2022-01-25 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のための高活性な合剤
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
WO2021216722A1 (en) * 2020-04-23 2021-10-28 Atea Pharmaceuticals, Inc. Stereoselective process of manufacture of purine phosphoramidates
CN112782311B (zh) * 2020-12-30 2022-12-27 南京百泽医药科技有限公司 一种富马酸丙酚替诺福韦中l-丙氨酸异丙酯的hplc测定方法
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
CN112940053B (zh) * 2021-02-26 2022-08-12 江苏阿尔法药业股份有限公司 一种抗hcv药物的制备方法
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
TW202317145A (zh) * 2021-06-17 2023-05-01 美商亞堤製藥公司 有利之抗hcv組合療法
WO2025014360A1 (en) 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297294C (en) 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
IN191496B (https=) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
EP1964569A3 (en) 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
WO2002032920A2 (en) 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
EP2180064A3 (en) 2000-10-18 2010-08-11 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1478322A4 (en) 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
AU2002365234B2 (en) 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections
CA2470938A1 (en) 2001-12-20 2003-07-03 Beth Israel Deaconess Medical Center Treatment of ebv and khsv infection and associated abnormal cellular proliferation
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
WO2004013300A2 (en) 2002-08-01 2004-02-12 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
WO2004014312A2 (en) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
TWI294882B (en) 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
ES2625429T3 (es) 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
AR043006A1 (es) 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
AU2003209667A1 (en) * 2003-02-21 2004-09-09 Hetero Drugs Limited Bicalutamide polymorphs
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
JP2006527719A (ja) 2003-06-19 2006-12-07 エフ．ホフマン−ラ　ロシュ　アーゲー ４’−アジドヌクレオシド誘導体の調製方法
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
DE10335061B4 (de) 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
CA2571079A1 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
CA2572583A1 (en) 2004-06-29 2006-01-12 Avery Dennison Corporation Nonwoven-elastomeric laminate with improved bonding between elastomer and nonwoven web
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
WO2006063149A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
CA2600886A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2006102533A2 (en) 2005-03-23 2006-09-28 Neopharm, Inc. Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates
WO2006104945A2 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
CA2618560A1 (en) 2005-08-09 2007-02-22 Merck & Co., Inc. Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection
WO2007022073A2 (en) 2005-08-12 2007-02-22 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
EP1987050A2 (en) 2006-02-14 2008-11-05 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007130783A2 (en) 2006-05-03 2007-11-15 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
KR101057239B1 (ko) 2006-10-10 2011-08-16 에프. 호프만-라 로슈 아게 뉴클레오사이드 리보푸라노실 피리미딘의 제조
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2007338899A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
CA2676822A1 (en) 2007-01-31 2008-08-07 Alios Biopharma, Inc. 2-5a analogs and their methods of use
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
HRP20120914T1 (hr) 2007-05-10 2012-12-31 Biocryst Pharmaceuticals, Inc. Spojevi tetrahidrofuro[3,4-d]dioksolana, namijenjeni upotrebi u lijeäśenju virusnih infekcija i raka
US20100279969A1 (en) 2007-05-14 2010-11-04 Rfs Pharma, Llc Azido purine nucleosides for treatment of viral infections
DK2014771T3 (en) 2007-06-25 2015-03-09 Anadys Pharmaceuticals Inc Continuous process for the enzymatic hydrolysis
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20090060866A1 (en) 2007-08-31 2009-03-05 Idenix Pharmaceuticals, Inc. Phosphadiazine hcv polymerase inhibitors i and ii
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
WO2009086201A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR072428A1 (es) 2008-07-01 2010-08-25 Medivir Ab Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326627A1 (en) 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2439009T3 (es) 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
WO2010068708A2 (en) 2008-12-09 2010-06-17 Rfs Pharma, Llc 3'-azido purine nucleotide prodrugs for treatment of viral infections
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
NZ593649A (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
US8759318B2 (en) 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
EP2393815A4 (en) 2009-02-06 2012-11-21 Rfs Pharma Llc PURIN NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF CANCER AND VIRUS INFECTIONS
MX2011008409A (es) 2009-02-10 2011-10-21 Gilead Sciences Inc Análogos de carba-nucléosido para tratamiento antiviral.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
WO2010108135A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
WO2011005595A2 (en) 2009-06-24 2011-01-13 Alios Biopharma, Inc. 2-5a analogs and their methods of use
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2614932T3 (es) 2009-09-29 2017-06-02 Janssen Products, L.P. Derivados de fosforoamidatos de nucleósidos
KR101961601B1 (ko) 2009-11-16 2019-03-25 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
US8563530B2 (en) * 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
PT2638054E (pt) 2010-11-10 2015-03-02 Medivir Ab Fosforamidatos de nucleósidos de uracilo espirooxetano
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
CA2819041A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2658857B1 (en) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
CA2836579A1 (en) 2011-05-19 2012-11-22 Rfs Pharma, Llc Purine monophosphate prodrugs for treatment of viral infections
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
WO2013019874A1 (en) 2011-08-01 2013-02-07 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
AU2012325801B2 (en) * 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013090420A2 (en) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
GB2497580A (en) 2011-12-16 2013-06-19 Intercede Ltd Data transmission using a plurality of barcodes displayed in a loop
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8673926B2 (en) 2012-02-14 2014-03-18 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
HUE047050T2 (hu) * 2012-02-27 2020-04-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2013173759A2 (en) 2012-05-17 2013-11-21 Enanta Pharmaceuticals, Inc. Macrocyclic nucleoside phosphoramidate derivatives
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
CN104640444B (zh) 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
EP2870169A1 (en) 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
HK1214270A1 (zh) 2012-10-29 2016-07-22 共晶制药股份有限公司 用於治療病毒感染和癌症的嘧啶核苷及其單磷酸酯前藥
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US9447132B2 (en) 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
CN103435672A (zh) 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150011481A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8889701B1 (en) 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) * 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
WO2015095305A1 (en) 2013-12-17 2015-06-25 Idenix Pharmaceuticals, Inc. Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
WO2015158913A1 (en) 2014-04-17 2015-10-22 Katholieke Universiteit Leuven Novel antiviral and antitumoral compounds
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
CN107108676A (zh) 2014-09-15 2017-08-29 美迪维尔公司 用于制备非对映异构纯的磷酰胺酯前药的方法
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CN106188192B (zh) 2015-04-29 2019-09-10 刘沛 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途
WO2018009623A1 (en) 2016-07-08 2018-01-11 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINE NUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) * 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021216722A1 (en) 2020-04-23 2021-10-28 Atea Pharmaceuticals, Inc. Stereoselective process of manufacture of purine phosphoramidates
JP7851034B2 (ja) 2020-08-19 2026-04-24 アテア ファーマシューティカルズ， インコーポレイテッド 選択されたプリンホスホルアミデートの立体選択的製造
EP4225282A4 (en) 2020-10-09 2024-10-16 ATEA Pharmaceuticals, Inc. DRUGS INTERFERING WITH NIRAN FOR MUTANT THERAPY AGAINST SARS-COV-2
AU2022213335A1 (en) 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt

Also Published As

Publication number Publication date
SMT202500048T1 (it) 2025-03-12
US12006340B2 (en) 2024-06-11
US20180215776A1 (en) 2018-08-02
CO2019009215A2 (es) 2019-08-30
KR102592899B1 (ko) 2023-10-24
EP4450129A2 (en) 2024-10-23
US20210277045A1 (en) 2021-09-09
BR112019014738A8 (pt) 2022-10-11
ZA202104494B (en) 2023-01-25
HRP20250266T1 (hr) 2025-04-25
LT3577124T (lt) 2025-02-10
MX2022009352A (es) 2022-09-02
JP2024102245A (ja) 2024-07-30
KR20190113864A (ko) 2019-10-08
NZ780244A (en) 2026-02-27
CN110248951B (zh) 2022-10-28
DK3577124T3 (da) 2025-02-24
ZA201904336B (en) 2020-12-23
EP3577124B1 (en) 2024-12-11
EP3577124A1 (en) 2019-12-11
ZA202207262B (en) 2023-11-29
CN110248951A (zh) 2019-09-17
AU2018215203A1 (en) 2019-07-18
RU2019127284A3 (https=) 2021-08-04
SI3577124T1 (sl) 2025-03-31
GEP20227457B (en) 2023-01-10
GEAP202215124A (en) 2022-07-11
IL295609B2 (en) 2023-11-01
JP2022078216A (ja) 2022-05-24
GEP20237457B (en) 2023-01-10
IL295609A (en) 2022-10-01
CA3048033C (en) 2023-06-20
CA3197567A1 (en) 2018-08-09
IL295609B1 (en) 2023-07-01
IL288737A (en) 2022-02-01
PT3577124T (pt) 2025-02-14
KR20210151247A (ko) 2021-12-13
PH12019550113A1 (en) 2019-12-02
US10894804B2 (en) 2021-01-19
EP4450129A3 (en) 2025-03-19
ES3009733T3 (en) 2025-03-31
US20200087339A1 (en) 2020-03-19
WO2018144640A1 (en) 2018-08-09
PL3577124T3 (pl) 2025-04-22
JP2020505423A (ja) 2020-02-20
AU2022271421A1 (en) 2022-12-22
JP7066728B2 (ja) 2022-05-13
TWI808072B (zh) 2023-07-11
KR102693011B1 (ko) 2024-08-08
RS66554B1 (sr) 2025-03-31
TW201832770A (zh) 2018-09-16
US20240018179A1 (en) 2024-01-18
SG11201906163TA (en) 2019-08-27
IL268077B (en) 2022-01-01
IL288737B (en) 2022-09-01
SG10202012214WA (en) 2021-01-28
AU2025201543A1 (en) 2025-03-20
MX2019009114A (es) 2019-10-09
KR102335193B1 (ko) 2021-12-03
US10519186B2 (en) 2019-12-31
RU2019127284A (ru) 2021-03-02
UA127407C2 (uk) 2023-08-16
BR112019014738A2 (pt) 2020-03-10
NZ754996A (en) 2022-03-25
US20200331954A1 (en) 2020-10-22
IL268077A (en) 2019-09-26
US20210087217A1 (en) 2021-03-25
US10906928B2 (en) 2021-02-02
CA3048033A1 (en) 2018-08-09
AU2018215203B2 (en) 2022-12-08
MX394394B (es) 2025-03-24
KR20230151050A (ko) 2023-10-31
TW202337472A (zh) 2023-10-01
HUE070331T2 (hu) 2025-05-28
EP3577124A4 (en) 2021-01-06
FI3577124T3 (fi) 2025-02-13
CN115477679A (zh) 2022-12-16
TWI866273B (zh) 2024-12-11

Similar Documents

Publication Publication Date Title
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
PH12018550150B1 (en) Elimination of hepatitis b virus with antiviral agents
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
EA201992329A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12015502230B1 (en) Novel viral replication inhibitors
MX2016010058A (es) Uso de alfavirus en preparaciones de fármacos antitumorales.
MY197236A (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
ZA201906327B (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
MX389844B (es) Regimen de dosificacion para interferon pegilado.
EA201991810A1 (ru) Гемисульфатная соль нуклеотида для лечения вируса гепатита с
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний
MY178600A (en) Antiviral composition against chikungunya virus